# US 2001/0055778 A1 · Method of detecting and /or quantifying a specific ige antibody in a liguid sample

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0055778 A1
- Document ID: US20010055778A1
- Status: Published application
- Kind: A1
- Application number: 09/467,901
- Filed: 1999-12-21
- Published: 2001-12-27
- Earliest claimed: 1998-12-22
- Assignees: ALK-Abello A/S
- Inventors: JOOST VAN NEERVEN
- Web page: https://patentgrep.com/patent/US20010055778A1

## CPC

- G01N 33/6854: {Immunoglobulins}
- G01N 33/566: using specific carrier or receptor proteins as ligand binding reagents {where possible specific carrier or receptor proteins are classified with their target compounds}
- Y10S 436/80: Fluorescent dyes, e.g. rhodamine
- Y10S 436/805: Optical property
- Y10S 436/806: Electrical property or magnetic property
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

A method of detecting and/or quantifying an IgE antibody specific to a ligand in the form of antigen, antibody or hapten in a liquid sample comprising the steps of (a) contacting (i) the sample with (ii) a ligand in the form of an antigen, an antibody or a hapten to form a mixture I comprising IgE-containing complexes, (b) mixing mixture I with a carrier to which is bound (iii) IgE receptor, said IgE receptor being CD23 (FcεRII) and/or FcεRI, to form a mixture II comprising carrier-bound IgE-containing complexes, (c) separating the carrier-bound IgE-containing complexes from mixture II, and (d) determining the amount of the carrier-bound IgE-containing complexes formed.

## Claims

### Claim 1

A method of detecting and/or quantifying an IgE antibody specific to a ligand in the form of antigen, antibody or hapten in a liquid sample comprising the steps of
(a) contacting (i) the sample with (ii) a free ligand in the form of an antigen, an antibody or a hapten to form a mixture I comprising IgE-containing complexes,
(b) mixing mixture I with a carrier to which is bound (iii) IgE receptor, said IgE receptor being CD23 (FcεRII) and/or FcεRI, to form a mixture II comprising carrier-bound IgE-containing complexes,
(c) separating the carrier-bound IgE-containing-complexes from mixture II, and
(d) determining the amount of the carrier-bound IgE-containing complexes formed.

### Claim 2 (depends on 1)

A method according to claim 1, wherein the ligand is labelled.

### Claim 3 (depends on 1)

A method according to claim 1, wherein the ligand used in step a) is bound to (iv) a label compound.

### Claim 4 (depends on 1)

A method according to claim 1, wherein (iv) a label compound is added in step a) in addition to (i) the sample and (ii) the ligand.

### Claim 5 (depends on 1)

A method according to claim 1, wherein a label compound is added to the carrier-bound IgE-containing complexes formed in step (b).

### Claim 6 (depends on 1)

A method according to claim 1, wherein (iv) a label compound is added to the carrier-bound IgE-containing complexes resulting from the separation step (c) to form a mixture II′.

### Claim 7 (depends on 6)

A method according to claim 6, wherein the labelled and carrier-bound IgE-containing complexes are separated from mixture II′ and washed prior to step (d).

### Claim 8 (depends on 3, 4, 5, 6, 7)

A method according to any of claims 3-7, wherein (iv) label compound is a chemiluminescent compound covalently bound to avidin, streptavidin or a functional derivative thereof.

### Claim 9 (depends on 8)

A method according to claim 8, wherein the chemiluminescent compound is an acridinium compound.

### Claim 10

A method according to any of the preceding claims, wherein the ligand is bound to biotin or a functional derivative thereof.

### Claim 11

A method according to any of the preceding claims, wherein the IgE-containing sample is contacted with the ligand and allowed to incubate to form a mixture I (step (a)) before contacting mixture I with the carrier/IgE receptor (step (b)).

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A method according to any of claims 1-10, wherein step (a) and (b) are carried out simultaneously in one operation.

### Claim 13

A method according to any of the preceding claims, wherein the carrier is a particulate material.

### Claim 14 (depends on 13)

A method according to claim 13, wherein the carrier is a paramagnetic particulate material.

### Claim 15

A method according to any of the preceding claims, wherein the IgE to be detected is quantified using both CD23 alone to obtain a first measurement and using FcεRI alone to obtain a second measurement.

### Claim 16

A method according to any of the preceding claims, wherein the number of ligand molecules is between 100% and 200% of the number of IgE molecules to be detected.

### Claim 17 (depends on 1)

A method according to claim 1 comprising using a detection system in the form of a label compound coupled to an antibody to the IgE to be detected.

### Claim 18 (depends on 17)

A method according to claim 17, wherein the label compound is coupled to the antibody via biotin.

### Claim 19 (depends on 17, 18)

A method according to claim 17 or 18, wherein the detection system is added to the carrier-bound complexes formed in step c).

### Claim 20

A method of detecting and/or quantifying a specific IgE antibody in a liquid sample comprising the steps of (a) contacting (i) the sample with (ii) a free ligand in the form of an antigen, an antibody or a hapten to form a mixture I comprising IgE-containing complexes, wherein the ligand is bound to biotin or a functional derivative thereof,
(b) mixing mixture I with a carrier to which is bound (iii) IgE receptor, said IgE receptor being CD23 (FcεRII) and/or FcεRI, to form a mixture II comprising carrier-bound IgE-containing complexes,
(b′) separating the carrier-bound IgE-containing complexes from mixture II and washing the said complexes,
(b″) adding to the washed carrier-bound IgE-containing complexes a solution of (iv) a chemiluminescent compound covalently bound to avidin, streptavidin or a functional derivative thereof to form a mixture II′,
(c) separating the carrier-bound IgE-containing complexes from mixture II′ and washing the said complexes,
(d) initiating a chemiluminescent reaction in the resulting IgE-containing complexes and detecting/measuring the resulting chemiluminescence, if any.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

Use of the method of any of claims 1-17 to monitor and evaluate the immunological status of a subject.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

Use of the method of any of claims 1-17 to monitor and evaluate the immunological status of a subject receiving Specific Allergy Vaccination (SAV) treatment.
